IBDEI1M0 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,239,0)
 ;;=NEPHRITIS INTERSTITIAL^19^26
 ;;^UTILITY(U,$J,358.4,240,0)
 ;;=NEPHROTIC SYNDROME^21^26
 ;;^UTILITY(U,$J,358.4,241,0)
 ;;=OBSTRUCTIVE UROPATHY^22^26
 ;;^UTILITY(U,$J,358.4,242,0)
 ;;=TRANSPLANT^26^26
 ;;^UTILITY(U,$J,358.4,243,0)
 ;;=CKD/KIDNEY DISEASE^3^26
 ;;^UTILITY(U,$J,358.4,244,0)
 ;;=HEMODIALYSIS-AKI^13^26
 ;;^UTILITY(U,$J,358.4,245,0)
 ;;=ACUTE KIDNEY INJURY^1^26
 ;;^UTILITY(U,$J,358.4,246,0)
 ;;=GLOMERULAR DISEASE^11^26
 ;;^UTILITY(U,$J,358.4,247,0)
 ;;=KIDNEY INVOLVMNT IN SYSTEMIC DISEASE^17^26
 ;;^UTILITY(U,$J,358.4,248,0)
 ;;=NEPHROLITHASIS^20^26
 ;;^UTILITY(U,$J,358.4,249,0)
 ;;=POISONING & INTOXICATIONS^24^26
 ;;^UTILITY(U,$J,358.4,250,0)
 ;;=DIALYSIS^7^26
 ;;^UTILITY(U,$J,358.4,251,0)
 ;;=SUICIDE IDEATIONS/ATTEMPTS^25^26
 ;;^UTILITY(U,$J,358.4,252,0)
 ;;=ACUTE RENAL FAILURE^1^27
 ;;^UTILITY(U,$J,358.4,253,0)
 ;;=CARDIOVASCULAR^3^27
 ;;^UTILITY(U,$J,358.4,254,0)
 ;;=CHRONIC KIDNEY DISEASE^4^27
 ;;^UTILITY(U,$J,358.4,255,0)
 ;;=CONTACT/EXPOSURE TO COM D^5^27
 ;;^UTILITY(U,$J,358.4,256,0)
 ;;=DERMATOLOGY^6^27
 ;;^UTILITY(U,$J,358.4,257,0)
 ;;=DIABETES W/ COMPLICATIONS^7^27
 ;;^UTILITY(U,$J,358.4,258,0)
 ;;=DIABETES W/O COMPLICATION^8^27
 ;;^UTILITY(U,$J,358.4,259,0)
 ;;=EENT^10^27
 ;;^UTILITY(U,$J,358.4,260,0)
 ;;=ENDOCRINE/METABOLIC^11^27
 ;;^UTILITY(U,$J,358.4,261,0)
 ;;=GASTROENTEROLOGY^12^27
 ;;^UTILITY(U,$J,358.4,262,0)
 ;;=GENITOURINARY^13^27
 ;;^UTILITY(U,$J,358.4,263,0)
 ;;=HEMATOLOGY/ONCOLOGY^14^27
 ;;^UTILITY(U,$J,358.4,264,0)
 ;;=HISTORY & STATUS POST^15^27
 ;;^UTILITY(U,$J,358.4,265,0)
 ;;=INFECTIOUS DISEASE^16^27
 ;;^UTILITY(U,$J,358.4,266,0)
 ;;=INFLAMMATORY/INF LUNG DX^17^27
 ;;^UTILITY(U,$J,358.4,267,0)
 ;;=INTERSTITIAL DISEASE^18^27
 ;;^UTILITY(U,$J,358.4,268,0)
 ;;=MENTAL HEALTH^19^27
 ;;^UTILITY(U,$J,358.4,269,0)
 ;;=MUSCULOSKELETAL^20^27
 ;;^UTILITY(U,$J,358.4,270,0)
 ;;=NEUROLOGY^21^27
 ;;^UTILITY(U,$J,358.4,271,0)
 ;;=OBSTRUCTIVE AIRWAY DISEASE^22^27
 ;;^UTILITY(U,$J,358.4,272,0)
 ;;=ORAL CAVITY^23^27
 ;;^UTILITY(U,$J,358.4,273,0)
 ;;=OTHER REASONS^24^27
 ;;^UTILITY(U,$J,358.4,274,0)
 ;;=PAIN^25^27
 ;;^UTILITY(U,$J,358.4,275,0)
 ;;=PERSONAL HISTORY^26^27
 ;;^UTILITY(U,$J,358.4,276,0)
 ;;=PLEURAL DISEASE^27^27
 ;;^UTILITY(U,$J,358.4,277,0)
 ;;=PNEUMONIA^28^27
 ;;^UTILITY(U,$J,358.4,278,0)
 ;;=PULMONARY VASCULAR DISEASE^30^27
 ;;^UTILITY(U,$J,358.4,279,0)
 ;;=RESPIRATORY^31^27
 ;;^UTILITY(U,$J,358.4,280,0)
 ;;=SECONDARY DIABETES^32^27
 ;;^UTILITY(U,$J,358.4,281,0)
 ;;=SIGNS, SYMPTOMS, CONDITIONS^33^27
 ;;^UTILITY(U,$J,358.4,282,0)
 ;;=SLEEP DISORDERS^34^27
 ;;^UTILITY(U,$J,358.4,283,0)
 ;;=THROMBO EMBOLIC DISEASE^35^27
 ;;^UTILITY(U,$J,358.4,284,0)
 ;;=TUMOR^36^27
 ;;^UTILITY(U,$J,358.4,285,0)
 ;;=VASCULAR^37^27
 ;;^UTILITY(U,$J,358.4,286,0)
 ;;=PRE-OP/POST-OP/COUNSELING^29^27
 ;;^UTILITY(U,$J,358.4,287,0)
 ;;=E-CONSULTS^9^27
 ;;^UTILITY(U,$J,358.4,288,0)
 ;;=ANTICOAGULATION^2^27
 ;;^UTILITY(U,$J,358.4,289,0)
 ;;=E-CONSULT MD/NP/PA^1^28
 ;;^UTILITY(U,$J,358.4,290,0)
 ;;=E-CONSULT NON-LIP^2^28
 ;;^UTILITY(U,$J,358.4,291,0)
 ;;=NEW PATIENT^2^29
 ;;^UTILITY(U,$J,358.4,292,0)
 ;;=ESTABLISHED PATIENT^1^29
 ;;^UTILITY(U,$J,358.4,293,0)
 ;;=CONSULTATIONS^3^29
 ;;^UTILITY(U,$J,358.4,294,0)
 ;;=ENDOCRINE DX^1^30
 ;;^UTILITY(U,$J,358.4,295,0)
 ;;=SUICIDE IDEATIONS/ATTEMPTS^2^30
 ;;^UTILITY(U,$J,358.4,296,0)
 ;;=BIOPSIES^1^31
 ;;^UTILITY(U,$J,358.4,297,0)
 ;;=INJECTIONS & INFUSIONS^2^31
